News and Trends 30 Nov 2022 bit.bio expands portfolio for drug discovery in neurodegenerative and neurological diseases …past six months with more to come in the new year.” Frontotemporal dementia (FTD) is the second leading cause of early onset dementia following Alzheimer’s disease. Patients with FTD suffer… November 30, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 Proxidrugs: a new tool to fight pathogens? …disposal system as potential new treatments for cancer, infections and Alzheimer’s disease. Aimo Kannt, head of drug discovery and preclinical research at Fraunhofer ITMP in Frankfurt, is currently researching the… September 1, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Biotech conferences and events 2022-2023 …York, US 10-12 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting, Boston, US 29-December 1 CRISPR 2.0 Boston, US 29-December 2 Clinical Trials on Alzheimer’s Disease international conference, San… December 13, 2023 - 1 minutemin - By Aurore Michelin Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2024 Top biotech deals of October 2024 …$1.4 billion as part of the agreement. This will see the neuroscience company’s anti-pyroglutamate amyloid beta (3pE-Aβ) antibody ALIA-1758 for Alzheimer’s disease now in the hands of the pharma giant… November 4, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2018 Ultrasound Brain Cancer Therapy Gets €9M Series B Funding …enter the market in 2022. With this Series B money, CarThera also hopes to develop its ultrasound technique for use in other brain diseases such as Alzheimer’s disease. Sottilini told… December 12, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 17 Apr 2019 What Does the Future Hold for European Biotech? Insights from Evotec’s CEO …some diseases, such as Alzheimer’s, current animal models are no good at predicting whether a drug will work in humans. But today, scientists are able to turn any human cell… April 17, 2019 - 7 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 Clinical trends for 2023 …example of Arrakis Therapeutics, which is using the approach to block the formation of a previously undruggable cancer protein called Myc. The recent clinical trial success from Biogen’s Alzheimer’s drug… January 11, 2023 - 8 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 2 Jun 2025 Top biotech deals in May 2025 …take command over Massachusetts-based Vigil Neuroscience after it signed a $470 million acquisition deal. Vigil’s pipeline, led by its small molecule TREM2 agonist for Alzheimer’s disease, will soon be in… June 2, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 22 Aug 2025 The Sanofi pipeline in 2025: Is the play-to-win strategy working? …a first-in-class, oral small-molecule agonist of TREM2, a lipid-sensing receptor on microglia. In Alzheimer’s, loss-of-function variants in TREM2 impair microglial responses, and activating TREM2 is expected to enhance microglia’s neuroprotective… August 22, 2025 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 8 May 2017 Top 5 Mistakes that Will Doom a CRO-Supplier Partnership Before it Starts …if you’re working in Alzheimer’s, make sure that the CRO knows how to select the right patients – experts seem to agree that Eli Lilly’s recent Phase III failure in… May 8, 2017 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Dec 2020 A Year to Remember: The Biggest European Biotech News in 2020 …IPO was followed in November by a €105M Series C round raised by the Berlin-based ATAI Life Sciences, another psychedelics player that owns a stake in Compass Pathways. The Alzheimer’s… December 28, 2020 - 12 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jul 2017 Why European Biotech Startups Should Attend American Conferences! …to gather contacts for our Alzheimer’s disease vaccine and to learn more about the state of the art in general,” Per Wester, CEO of Alzinova AB, told us in an… July 13, 2017 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email